Latest
market study on " Global Alpha 1-Antitrypsin (AAT) Replacement Therapy Market Report: 2016 " available with
Single User Global USD 800 at OrbisResearch.com
Scope of the Report
The report titled “Global Alpha 1-Antitrypsin (AAT) Replacement Therapy Market: Size, Trends and Forecast (2016-2020)” provides an in-depth analysis of the global AAT Replacement Therapy market with detailed analysis of market sizing, growth and market share. The report provides market size by value and volume along with the supply trend prevailing in the market.
Get More
Information of Global Alpha 1-Antitrypsin (AAT) Replacement Therapy Market
Report @ http://www.orbisresearch.com/reports/index/global-alpha-1-antitrypsin-aat-replacement-therapy-market-size-trends-and-forecast-2016-2020
.
The report provides detail market analysis of the major products
available in the market for treating AAT deficiency. The four major products
included are, Prolastin, Glassia, Zemaira, and Aralast. Among which, Prolastin
had the monopoly in the market for over 25 years, Asit was the first AAT
Replacement Therapy available in the market for the treatement.
The report also assesses the key opportunities in the market and outlines
the factors that are and will be driving the growth of the industry. Growth of
the overall global AAT Replacement Therapy market has also been forecasted for
the period 2016-2020, taking into consideration the previous growth patterns, the
growth drivers and the current and future trends. The competition in the global
AAT Replacement Therapy market is stiff and dominated by the big players like
Grifols. Further, key players of the AAT Replacement Therapy market, Kamada,
Shire and CSL Behring are also profiled with their financial information and
respective business strategies.
Request a sample of
Global Alpha 1-Antitrypsin (AAT) Replacement Therapy market @ http://www.orbisresearch.com/contacts/request-sample/185447 .
Regional Coverage
Global
Global
Company Coverage
Grifols SA
Kamada Ltd.
CSL Behring LLC
Shire PLC
Grifols SA
Kamada Ltd.
CSL Behring LLC
Shire PLC
Executive Summary
Alpha 1 antitrypsin is a type of plasma protein inside our body, it is called protease inhibitor. AAT is made in the liver and its function is to protect lungs and liver. Deficiency of AAT protein is caused by genetic defect. Adults with severe AAT deficiency develop emphysema. Smoking can increase the risk of emphysema. The market to replace AAT deficiency by replacement therapy has grown with in past 5-10 years.
Alpha 1 antitrypsin is a type of plasma protein inside our body, it is called protease inhibitor. AAT is made in the liver and its function is to protect lungs and liver. Deficiency of AAT protein is caused by genetic defect. Adults with severe AAT deficiency develop emphysema. Smoking can increase the risk of emphysema. The market to replace AAT deficiency by replacement therapy has grown with in past 5-10 years.
The global AAT Replacement therapy market has increased at a significant
CAGR during the span of 4 years i.e. 2012-2015 and projections are made that
the market would rise in the next five years i.e. 2016-2020 tremendously. The
market for AAT replacement therapy has increased significantly in these years
because the people as well as doctors have become more aware of the disease.
Earlier, patients suffering from AAT deficiency were treated like asthma
patients or other COPD patients. But, now, doctors have access to better
diagnostics tests that can detect disease at the early stage.
Improvement in the method of treatment is the major driver for the growth
of the market, a number of technologies and diagnostics have been innovated to
treat and diagnose the same. Thus, the increased awareness along with improved
treatment signifies the upsurge in the AAT Replacement Therapy market. Also,
the number the of prescriptions for AAT Replacement therapy have been reported
to increase at an increasing rate, driving the market in the positive
direction. Despite the market is governed by various growth drivers, there are
certain challenges faced by the market such as: the cost of the treatment is high
for people, limited plasma fraction capacity and side-effects of alpha1
proteinase inhibitor.
Purchase
a copy of Global Alpha 1-Antitrypsin (AAT) Replacement Therapy Market visit @ http://www.orbisresearch.com/contact/purchase/185447 .
For
more information contact sales@orbisresearch.com .
Table
of Contents:
1. Executive
Summary
2. Introduction
2.1 Introduction to Alpha-1 Antitrypsin (AAT) Deficiency
2.1.1 Impacts of AAT Deficiency
2.1.2 Diagnosis and Treatment of AAT Deficiency
2.2 AAT Replacement Therapy Overview
2.2.1 AAT Replacement Therapy
2.2.2 AAT Replacement Therapy Products
2.1 Introduction to Alpha-1 Antitrypsin (AAT) Deficiency
2.1.1 Impacts of AAT Deficiency
2.1.2 Diagnosis and Treatment of AAT Deficiency
2.2 AAT Replacement Therapy Overview
2.2.1 AAT Replacement Therapy
2.2.2 AAT Replacement Therapy Products
About Us:
Orbis Research (orbisresearch.com) is a
single point aid for all your market research requirements. We have vast
database of reports from the leading publishers and authors across the globe.
We specialize in delivering customized reports as per the requirements of our
clients. We have complete information about our publishers and hence are sure
about the accuracy of the industries and verticals of their specialization.
This helps our clients to map their needs and we produce the perfect required
market research study for our clients.
Contact
Information:
Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1
(214) 884-6817; +9164101019
such a nice post about "Global Alpha 1-Antitrypsin (AAT) Replacement Therapy Market"
ReplyDeletethanks,
99% Accurate Commodity Tips | Commodity Tips Free Trial
waoo ncie post about Global Alpha 1-Antitrypsin (AAT) Replacement Therapy Market 2016
ReplyDeleteThanks,
Crude Oil Tips Free Trial